EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics

Shayan Asadi iD, Mina Taheri-Torbati, Prashant Kesharwani iD, Amirhossein Sahebkar iD

Drug Development Research · 2025-12 · 86 (8)

DOI: 10.1002/ddr.70197 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 21.11.2025. Verfasst von Shayan Asadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Iran. Hauptthemen laut MEDLINE: Lysosomes, Proteolysis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 135 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) is an emerging drug discovery approach aimed at enabling the selective removal of disease‐associated proteins. While proteolysis‐targeting chimeras (PROTACs) have advanced intracellular degradation via the ubiquitin–proteasome system, their limitation to cytosolic proteins excludes ~40% of the human proteome that is extracellular or membrane‐bound. Lysosome‐targeting chimeras (LYTACs) address this gap by harnessing lysosomal trafficking receptors, thereby mediating the degradation of extracellular and membrane proteins. More recently, methylarginine‐targeting chimeras (MrTACs) have extended lysosomal strategies to certain intracellular targets, bypassing proteasomal dependence. This review critically examines the mechanistic underpinnings, design strategies, and bioanalytical challenges associated with lysosome‐mediated degradation platforms. Emphasis is placed on their therapeutic implications, analytical evaluation, and potential for expanding druggable targets. Together, these emerging lysosomal chimeras offer a paradigm shift in TPD, with far‐reaching applications in precision medicine and chemical biology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysosomesProteolysisHumansAnimalsDrug Discovery

Stichwörter der Autor:innen

chimeric degradersextracellular protein clearancelysosome‐targeting chimeras (LYTACs)precision medicinetargeted protein degradation

Autor:innen und Institutionen

  • Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, India.
  • Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
  • Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Applied Biomedical Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID-Profile: Shayan Asadi, Prashant Kesharwani, Amirhossein Sahebkar

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Asadi, S., Taheri-Torbati, M., Kesharwani, P., & Sahebkar, A. (2025). Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics. Drug Development Research, 86(8). https://doi.org/10.1002/ddr.70197

Vancouver

Asadi S, Taheri-Torbati M, Kesharwani P, Sahebkar A. Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics. Drug Development Research. 2025;86(8). doi:10.1002/ddr.70197

BibTeX
@article{Asadi2025,
  author = {Asadi, Shayan and Taheri-Torbati, Mina and Kesharwani, Prashant and Sahebkar, Amirhossein},
  title = {Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics},
  journal = {Drug Development Research},
  year = {2025},
  volume = {86},
  number = {8},
  doi = {10.1002/ddr.70197}
}
Kostenlos starten →